Working across formulation, ingredient evaluation and product development, I have seen how quickly the language of biotechnology has entered the beauty industry, and how unevenly it is understood. In some cases, it reflects a genuine shift in how materials are designed and produced. In others, it is applied more loosely, without a clear connection to the underlying science or formulation reality. This distinction matters, because biotechnology is not simply a new category of ingredients. It represents a different way of approaching cosmetic development, one that introduces both new opportunities and new constraints.

The integration of biotechnology into cosmetic science is therefore best understood as a structural shift in how ingredients are sourced, designed and evaluated. Unlike previous cycles of innovation that focused largely on sensorial improvements or incremental reformulation of known actives, biotechnology introduces controlled biological production systems capable of generating materials with defined structure, reproducibility and scalability. These capabilities extend beyond performance alone and begin to influence sustainability, supply chain resilience and the level of scientific rigor expected from finished products.

In practice, many aspects of biotechnology are already embedded within modern cosmetic ingredient manufacturing. Microbial fermentation and enzymatic synthesis are well established in the production of materials such as hyaluronic acid, amino acids and certain lipids. Compared to traditional plant or animal extraction, these approaches offer improved purity, reduced batch variability and independence from agricultural constraints. Fermentation-derived hyaluronic acid has, in many cases, replaced animal-derived sources for these reasons, reflecting not a future direction but a current standard (1), (2).

Where biotechnology becomes more distinct is in its ability to produce structurally and functionally relevant biomolecules. This includes bio-derived polymers, fermentation-derived skin-identical components and increasingly complex biological materials designed to interact with skin beyond surface-level effects. At this stage, clarity becomes critical. Not all high-performance ingredients are biotechnological, and not all biological narratives translate into functional benefit. Conflating synthetic actives with biologically produced materials risks overstating the level of innovation involved, a distinction that has been discussed in prior industry commentary (3).

A similar pattern can be observed in the evolution of microbiome-related claims. Early interest in live probiotics highlighted the difficulty of maintaining viable organisms in conventional topical systems. This has led to a more practical shift toward postbiotic ingredients, defined as non-viable microbial cells or their metabolites. These materials can be incorporated into standard formulations while still demonstrating potential to support barrier function and modulate inflammatory pathways, offering a more realistic translation of microbiome science into cosmetic applications (4).

As biotechnology has gained visibility, however, a widening gap has emerged between biological plausibility and formulation feasibility. This is particularly evident in the growing number of products positioned around extracellular vesicles and exosomes. These vesicles are well-characterized mediators of intercellular communication and have demonstrated relevance in regenerative medicine and tissue repair (5). Their proposed use in topical cosmetics is therefore conceptually compelling. Yet published data indicate that vesicle integrity, composition and functional activity are highly sensitive to isolation methods, storage conditions and handling processes (6), (7). This variability introduces challenges in reproducibility and consistency, and current evidence supporting efficacy in over-the-counter topical applications remains limited.

This gap highlights a fundamental principle that is often overlooked in discussions of biotechnology. Ingredient innovation cannot be evaluated independently of formulation. The performance of any biologically derived material depends on its ability to remain structurally intact and functionally relevant within the final system. Delivery technologies such as liposomes and nanoemulsions have demonstrated the ability to influence penetration and bioavailability, but their effectiveness is inherently dependent on system design, composition and compatibility with the active itself (8). In this context, formulation is not secondary to innovation. It is the mechanism through which innovation either succeeds or fails.

The increasing use of artificial intelligence in ingredient discovery and formulation development adds another layer to this landscape. Machine learning approaches are being applied to model molecular interactions, predict functionality and accelerate screening processes. While these tools offer clear efficiency advantages, their outputs remain dependent on the datasets used for training. In cosmetics, where clinical testing has historically underrepresented diverse skin types and tones, there is a risk that AI-driven approaches may replicate existing limitations rather than resolve them. Progress in this area will require not only computational advancement, but also more inclusive and representative data generation.

From a formulation perspective, biotechnology does not present a single set of challenges, but rather a range that depends on the material class. Fermentation-derived small molecules and polymers are generally compatible with conventional formulation approaches. More structurally complex materials, including peptides, proteins and extracellular vesicles, require closer attention to degradation pathways such as hydrolysis, oxidation, aggregation and interfacial stress. For extracellular vesicles in particular, storage conditions and handling have been shown to influence particle recovery, membrane integrity and functional properties (6), (7). These factors necessitate tailored formulation strategies and appropriate analytical controls to ensure consistency over shelf life.

Looking ahead, biotechnology is beginning to shift the focus of cosmetic science from visible correction toward modulation of underlying biological processes. Areas such as cellular senescence, chronic low-grade inflammation and mitochondrial function are receiving increasing attention. While these targets remain under investigation, they reflect a broader movement toward a systems-level understanding of skin health, supported by advances in bio-derived actives and improved mechanistic insight.

Biotechnology has the potential to elevate cosmetic science into a more precise and biologically grounded discipline. Realizing that potential requires alignment between ingredient design, formulation strategy and evidentiary standards. As the industry continues to adopt the language of biotechnology, it must ensure that claims are supported by reproducible data and that formulation approaches are capable of preserving the integrity and function of the materials being used. Without this alignment, the distinction between meaningful innovation and conceptual positioning becomes increasingly difficult to maintain.